- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07939867
Pharmacokinetics of Engasertib in Participants With and Without Hepatic Impairment
A Phase 1, Open-label, Parallel Cohort Study to Compare the Pharmacokinetics of Engasertib in Adult Participants With Mild to Moderate Hepatic Impairment Relative to Participants Without Hepatic Impairment
The main objective of this trial is to compare the pharmacokinetics (PK) of engasertib in plasma following administration of a single oral dose in adult participants with mild to moderate hepatic impairment relative to age- and body weight-matched participants without hepatic impairment.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Vaderis Therapeutics AG
- 전화번호: +1 844-823-3747
- 이메일: info@vaderis.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age of 18 to 70 years (both inclusive), at the time of signing the informed consent.
- Body weight ≥ 50 kg and a body mass index (BMI) within the range 18 to 35 kg/m^2 (both inclusive) at screening.
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
- Non-smoker, former smoker or stable non-smoker for at least 3 months prior to screening. Participants must also have abstained from use of other nicotine containing products for at least 3 months before screening.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol prior to any clinical trial specific procedure.
Participants without hepatic impairment (Cohort 1) only:
- Overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and electrocardiogram (ECG).
- Clinically acceptable results of clinical chemistry, hematology, coagulation, and urinalysis at screening.
- No known or suspected hepatic impairment; including at screening, meet all the following criteria, as assessed by central laboratory: a) alanine aminotransferase (ALT) ≤ 1.1 x upper limit of normal (ULN); b) aspartate aminotransferase (AST) ≤ 1.2 x ULN; c) Total serum bilirubin ≤ 1.2 x ULN; d) Serum albumin ≥ lower limit of normal (LLN); e) Prothrombin time ≤ 1.2 x ULN.
- Participant meets the demographic-matching criteria, including body weight (kg) ± 20 % and age ± 15 years of the average of the pooled hepatic impairment cohorts (Cohorts 2 and 3). Attempts will be made to ensure that the male-to-female distribution in Cohort 1, is comparable (i.e., ± 1) to that in the pooled hepatic impairment cohorts (Cohorts 2 and 3).
Participants with impaired hepatic function (Cohorts 2 and 3 only):
- Documented diagnosis of hepatic impairment that meets the criteria for Class A or B of the Child-Pugh classification, with no clinically significant change in disease status within the 28 days prior to the screening visit, as documented by the participant's recent medical history (e.g., no worsening clinical signs of hepatic impairment, no worsening of total bilirubin or prothrombin time by more than 50%).
- Participant is willing and able to abide by the lifestyle guidelines described in the protocol.
Exclusion Criteria:
- Clinically relevant medical condition or malignancy that may significantly alter the absorption, metabolism or elimination of engasertib, constitute a safety risk, or interfere with interpretation of trial results.
- History or evidence of malabsorption, or gastrointestinal surgery or disease that may significantly affect the absorption, distribution, metabolism or excretion of engasertib.
- Known or suspected hypersensitivity to engasertib or any component of its formulation.
- Clinically significant infection or immunodeficiency, including relevant active viral infection.
- Use of prohibited concomitant medications or therapies that may interfere with the pharmacokinetics of engasertib within the protocol-defined period before dosing.
- Use of another investigational drug or participation in another clinical trial within 30 days or 5 half-lives of the prior trial intervention, whichever is longer.
- Clinically significant abnormalities in vital signs, ECG, or renal function that preclude participation.
- Positive screening for alcohol or drugs of abuse, except where a positive drug screen in participants with hepatic impairment can be explained by permitted concomitant medication.
- Positive pregnancy test in a female participant of childbearing potential.
- For Cohorts 2 and 3: clinically relevant disease other than hepatic impairment and its associated manifestations that may affect safety, PK interpretation, or Child-Pugh assessment.
- For Cohorts 2 and 3: potentially infectious liver disease, including hepatitis B or C.
- For Cohorts 2 and 3: hepatic carcinoma, hepatorenal syndrome, predicted life expectancy of less than 1 year, severe portal hypertension, severe ascites requiring frequent paracentesis, severe hepatic encephalopathy, recent gastrointestinal hemorrhage, or previous kidney, liver, or heart transplantation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1: No Hepatic Impairment
Participants without hepatic impairment will take a single oral dose of engasertib 40 mg. |
Engasertib will be taken orally as capsules.
다른 이름들:
|
|
실험적: Cohort 2: Mild Hepatic Impairment
Participants with mild hepatic impairment will take a single oral dose of engasertib 40 mg. |
Engasertib will be taken orally as capsules.
다른 이름들:
|
|
실험적: Cohort 3: Moderate Hepatic Impairment
Participants with moderate hepatic impairment will take a single oral dose of engasertib 40 mg. |
Engasertib will be taken orally as capsules.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Area Under the Concentration-time Curve (AUC) from Zero to the Last Quantifiable Concentration (AUC0-tlast) of Engasertib
기간: Up to Day 12
|
Up to Day 12
|
|
AUC from Zero to Infinity (AUC0-inf) of Engasertib
기간: Up to Day 12
|
Up to Day 12
|
|
Maximum Plasma Concentration (Cmax) of Engasertib
기간: Up to Day 12
|
Up to Day 12
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Amount Excreted (Ae) in Urine from Time Zero to 72 h (Ae0-72)of Engasertib
기간: Up to Day 4
|
Up to Day 4
|
|
Fraction Excreted (Fe) in Urine from Time Zero to 72 h [Fe (%)] of Engasertib
기간: Up to Day 4
|
Up to Day 4
|
|
Renal Clearance (CLr) of Engasertib
기간: Up to Day 4
|
Up to Day 4
|
|
Percentage of Participants who Experienced Teatment Emergent Adverse Events (TEAEs) and Serious TEAEs
기간: Up to Day 12
|
Up to Day 12
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Katarzyna Jarus-Dziedzic, MD, PhD, BioResearch Group Sp. z o.o.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- ENG-103
- 2026-526312-37-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .